Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial

非布索坦 医学 内科学 析因分析 临床终点 危险系数 无症状的 高尿酸血症 随机对照试验 尿酸 置信区间
作者
Sunao Kojima,Kazuaki Uchiyama,Naoto Yokota,Eiichi Tokutake,Yutaka Wakasa,Shinya Hiramitsu,Masako Waki,Hideaki Jinnouchi,Hirokazu Kakuda,Takahiro Hayashi,Naoki Kawai,Masahiro Sugawara,Hisao Mori,Kenichi Tsujita,Kunihiko Matsui,Ichiro Hisatome,Yusuke Ohya,Kazuo Kimura,Yoshihiko Saito,Hisao Ogawa
出处
期刊:Rheumatology [Oxford University Press]
卷期号:61 (6): 2346-2359 被引量:18
标识
DOI:10.1093/rheumatology/keab739
摘要

OBJECTIVES: Hyperuricaemia is recognized as an independent risk marker for cardiovascular and renal diseases. However, uric acid is a powerful free-radical scavenger, and the optimal level of serum uric acid (SUA) determining outcomes is unknown. This study explored whether interventional treatments for excessive SUA reduction were harmful and what constituted the optimal lowering of SUA levels for the prevention of events in patients with asymptomatic hyperuricaemia. METHODS: This was a post hoc analysis of a randomized trial (Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy [FREED]) in which 1070 older patients with asymptomatic hyperuricaemia were enrolled and allocated to febuxostat (n = 537) or non-febuxostat treatment group (n = 533). We assessed the relationship between the endpoint (withdrawal or study completion) SUA levels and clinical outcomes. Primary endpoint was defined as a composite of all-cause mortality, cerebral and cardiorenovascular events. RESULTS: In the febuxostat group, patients achieving SUA levels ≤4 mg/dl (hazard ratio: 2.01 [95% CI: 1.05, 3.87]), >4 to ≤5 mg/dl (2.12 [1.07, 4.20], >6 to ≤7 mg/dl (2.42 [1.05, 5.60]), and >7 mg/dl (4.73 [2.13, 10.5]) had significantly higher risks for a primary composite event than those achieving SUA levels >5 to ≤6 mg/dl (P = 0.003 [log-rank test]). This J-shaped relationship applied to patients with renal impairment (P = 0.007 [Gray's test]) and was not significant in the non-febuxostat treatment group (P = 0.212 [log-rank test]). CONCLUSION: Optimal SUA level by febuxostat treatment is 5-6 mg/dl for reducing all-cause mortality, cerebral, cardiovascular and renal events. Excessive SUA reduction may be harmful in older hyperuricaemic populations. TRIAL REGISTRATION: ClinicalTrial.gov, https://clinicaltrials.gov, NCT01984749.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Saber完成签到,获得积分10
1秒前
智慧门完成签到 ,获得积分10
1秒前
积极毛巾发布了新的文献求助10
1秒前
2秒前
枯桃发布了新的文献求助10
2秒前
lmy发布了新的文献求助10
2秒前
mgqqlwq发布了新的文献求助10
3秒前
洪小乖完成签到 ,获得积分10
4秒前
直率翠绿发布了新的文献求助10
4秒前
TreKex发布了新的文献求助10
4秒前
4秒前
xixi完成签到,获得积分10
4秒前
6秒前
6秒前
7秒前
7秒前
hhhhhuo完成签到,获得积分10
8秒前
聪明笨蛋发布了新的文献求助10
9秒前
冷静妙旋完成签到,获得积分10
10秒前
积极毛巾完成签到,获得积分10
10秒前
10秒前
gxmu6322发布了新的文献求助10
10秒前
贾贡献的应助被DW采纳,获得10
11秒前
水煮电吹风的应助被路人采纳,获得10
11秒前
大气大侠发布了新的文献求助10
11秒前
整齐成仁发布了新的文献求助10
12秒前
aq完成签到,获得积分10
12秒前
13秒前
理想三寻完成签到,获得积分10
13秒前
英俊的铭的应助被第一作者采纳,获得10
13秒前
wangfei发布了新的文献求助10
13秒前
15秒前
15秒前
TreKex完成签到,获得积分10
16秒前
Lonze完成签到,获得积分10
16秒前
李沅翰完成签到,获得积分10
18秒前
泰想成功发布了新的文献求助10
18秒前
可爱的函函的应助被WT采纳,获得10
18秒前
xnyscmbs完成签到 ,获得积分20
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157